1-Ethoxymethyl-cyclohexanon-(4) | 17159-86-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Ethoxymethyl-cyclohexanon-(4)
• 英文别名: 4-(ethoxymethyl)cyclohexanone；4-(ethoxymethyl)cyclohexan-1-one
• CAS: 17159-86-3
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: QCBXWOMFZYTPSS-UHFFFAOYSA-N

物化性质

• 沸点：
  223.9±13.0 °C(Predicted)
• 密度：
  0.956±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Ethoxymethyl-cyclohexanon-(4) 在 sulfur 、 三乙胺 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Tetrahydrobenzothiophene carboxamides: Beyond the kinase domain and into the fatty acid realm

  摘要：

  A series of tetrahydrobenzothiophene carboxamides, inspired by structural features present in kinase and SCD1 inhibitors, are presented here. Prototype compound 8 (MMDD13) modulates fatty acid elongase and desaturase indexes, lipid accumulation, while preserving kinase inhibitory activity. This chemotype represents a stepping stone towards chemical probes to study the consequences of lipid metabolism modulation through non-redundant pathways. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.08.006
• 作为产物：
  描述：

  1,4-dioxaspiro[4.5]decan-8-ylmethyl 4-methylbenzenesulfonate 在 氢氧化钾 、 硫酸 作用下， 生成 1-Ethoxymethyl-cyclohexanon-(4)
  参考文献：
  名称：

  Musso,H. et al., Chemische Berichte, 1967, vol. 100, p. 3614 - 3624

  摘要：

  DOI：

文献信息

• [EN] CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES DU CCR2 À BASE DE CYCLOHEXYL-AZÉTIDINYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011159854A1

  公开（公告）日：2011-12-22

  The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括公式(I)的化合物。其中：R1、R2、R4、J、Q和A如说明书所述定义。本发明还包括预防、治疗或改善综合征、障碍或疾病的方法，其中所述综合征、障碍或疾病为2型糖尿病、肥胖和哮喘。本发明还包括通过管理治疗有效量的至少一种公式(I)化合物来抑制哺乳动物中的CCR2活性的方法。
• CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20110306592A1

  公开（公告）日：2011-12-15

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：R1、R2、X和Z如规范中所定义。该发明还包括一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病为II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• NOVEL COMPOUNDS-300
  申请人：Cheng Yun-Xing

  公开号：US20090275574A1

  公开（公告）日：2009-11-05

  Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 , R 3 , R 4 , m, n, q, s, t, X, and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  式I的化合物，或其药用盐：其中R1、R2、R3、R4、m、n、q、s、t、X和Y的定义如规范中所述，以及包括这些化合物的盐和药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。
• CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  申请人：Lanter James C.

  公开号：US20110312936A1

  公开（公告）日：2011-12-22

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 4 , J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明涉及I式化合物，其中：R1、R2、R4、J、Q和A如规范中所定义。本发明还涉及一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖和哮喘。本发明还涉及通过给哺乳动物施加至少一种I式化合物的治疗有效量来抑制CCR2活性的方法。
• Cyclohexyl-azetidinyl antagonists of CCR2
  申请人：Janssen Pharmaceutica NV

  公开号：US09062048B2

  公开（公告）日：2015-06-23

  The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明涉及公式I的化合物，其中：R1、R2、R4、J、Q和A如规范中所定义。该发明还涉及一种预防、治疗或改善综合症、疾病或疾患的方法，其中所述综合症、疾病或疾患是2型糖尿病、肥胖症和哮喘。该发明还涉及通过给哺乳动物施用公式I中至少一种化合物的治疗有效量来抑制CCR2活性的方法。